ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. - Wikidata - wikimedia - TriplyDB

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

http://www.wikidata.org/entity/Q27852699

about

Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?CIViC database A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib.Beyond RAS and BRAF: a target rich disease that is ripe for picking TRKing down an old oncogene in a new era of targeted therapy Fluorescence in situ hybridization in surgical pathology: principles and applications.Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA.ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.A time-resolved luminescence biosensor assay for anaplastic lymphoma kinase (ALK) activity.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas.Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population.Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.Oncodomains: A protein domain-centric framework for analyzing rare variants in tumor samples.Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features Identification and characterization of RET fusions in advanced colorectal cancer ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.Role of WDHD1 in Human Papillomavirus-Mediated Oncogenesis Identified by Transcriptional Profiling of E7-Expressing Cells.Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF Colorectal clinical trials: what is on the horizon?Recent Advances in Targeting ROS1 in Lung Cancer.Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives.Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer.ROS1 fusions in cancer: a review.Targeting ALK: Precision Medicine Takes on Drug Resistance.Intrahepatic cholangiocarcinoma: current management and emerging therapies.Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases.The democratization of the oncogene.A patient with classic biphasic pulmonary blastoma harboring CD74-ROS1 fusion responds to crizotinib.ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms.Immunohistochemical Detection of ROS1 Fusion.ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.

P2860

c57b135f5a9952839a9016526afddfe0cc3a8013

P248

Q26747329-EDB2D0A0-0157-40A0-9465-DB05D466C4F5 Q27023383-28513511-6E7D-445A-B092-39D46D1838FC Q27612411-8D0B07C8-1AF9-4F17-8EED-E693231E5C8B Q27853092-01F5F4FE-310C-4E3E-A65A-C6644037EF09 Q28066095-40C73F53-B98F-4DF4-B989-117633B8C5B9 Q28254287-4740499A-D356-4920-8EAC-FA0ED6810945 Q33593910-08344718-B2EA-4DD5-9CAD-23C9A1394A5F Q33898865-44ACEFF0-484F-4B25-B09E-801655921E9E Q34431889-31D6FFD2-4F54-4C23-9CC7-BA4DAE6DF1D1 Q34886379-F2982266-E857-4D99-88F6-DF454D52D29B Q35136424-332E6716-3E8D-482D-A525-A9011D89BA76 Q35136824-ECDB73A3-8265-4B81-A89D-E8A71102EBF7 Q35137474-E41D6471-1260-4355-BB5B-4EA4B87B9A58 Q35751428-2110AD23-F091-40D7-BA4D-DC78C6A0CFBA Q35811132-4CBA7689-AF98-4351-92E2-957F3F60E66B Q35871758-D233A88F-29D8-4ABA-96ED-E7909AD34C8F Q36145016-4AEEB4E6-D06D-419B-B411-4D9A0576345D Q36351953-2AB727F5-757E-408B-8A1F-61231D2F409E Q36414458-2C548544-83D8-4F80-91FB-FE3A6E931530 Q36432094-A7C16DCE-A992-4DB8-90C5-A42786A0E3F0 Q36444609-78F69DD5-1942-483F-8B9C-45283A5529D6 Q36557174-8390492B-B524-4384-994E-B8206C1E5A9C Q36629689-1E048DEC-A0DB-4197-BCCF-C701C36E5FDA Q36843773-6A519A56-B8EF-4CB5-9128-E8EF4771E75F Q37002546-9161EE22-E9FE-48A9-ACC6-6050264577B7 Q37149773-0C84EDF2-A239-41E5-8271-21C781323EC7 Q37157958-87D9001C-A8DA-43DA-AEA6-3CA35B9B43C2 Q38640765-56CE5CD6-2798-4402-8F6A-D7156D8EECDD Q38652369-68C6ED7E-40AF-44E1-8D4A-9346171B9059 Q38792120-49ADFA07-7285-433E-8E42-1403E883840C Q38852070-2DB56D02-551B-4780-AA7D-F10C1C972435 Q39103431-9547D61C-2352-4E13-BC68-788319FF7451 Q39186928-3837FD69-7AE0-46E9-B315-3988C3A6F81F Q40242246-49E2A8A8-2337-4700-8006-F884AA15BCC4 Q41912508-EA265236-4735-405E-ABF9-AA2D2847A4A1 Q47552108-35D95975-D3D3-4543-BA5A-518FC38DF247 Q47621661-EF7AA12B-9338-44F1-95FC-CA8486E5137A Q48385673-C9B885EC-2D4E-4894-B8D1-6691A033B7C8 Q49691234-4A61E224-6B78-47F9-936A-BD53411467A0 Q49887888-7ED69424-F5B2-499D-A235-C4E243832E84

P2860

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

http://www.wikidata.org/entity/Q27852699

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

ROS1 and ALK fusions in colore ...... geneity for molecular drivers.

@ast

ROS1 and ALK fusions in colore ...... geneity for molecular drivers.

@en

ROS1 and ALK fusions in colore ...... geneity for molecular drivers.

@nl

type

label

ROS1 and ALK fusions in colore ...... geneity for molecular drivers.

@ast

ROS1 and ALK fusions in colore ...... geneity for molecular drivers.

@en

ROS1 and ALK fusions in colore ...... geneity for molecular drivers.

@nl

altLabel

ROS1 and ALK Fusions in Colore ...... ogeneity for Molecular Drivers

@en

prefLabel

ROS1 and ALK fusions in colore ...... geneity for molecular drivers.

@ast

ROS1 and ALK fusions in colore ...... geneity for molecular drivers.

@en

ROS1 and ALK fusions in colore ...... geneity for molecular drivers.

@nl

P1433

Q27852699-23CF01F1-27D4-4316-B379-0B188A2682D0

P1476

Q27852699-7EF5EAC6-55C4-4F90-A142-C8B587545C0D

P2093

Q27852699-0347195D-317C-4357-9ED2-9B6F22C50D23

Q27852699-1699E5B2-92FF-4085-A69E-0168B11F3DCC

Q27852699-64355333-A610-4BF6-9746-0513BC4FFBD2

Q27852699-6DA74BDC-AE8F-43F9-B47E-E5E463D2C193

Q27852699-6DF43164-B4AA-451F-98D2-70759F245FA3

Q27852699-70D7815E-D321-4C5B-BCC3-EB09DD57EC77

Q27852699-A9E0B263-8396-4121-8FDE-AAA4EF6DF682

Q27852699-D8CB6A14-30FE-4CED-9681-D314442C19CF

Q27852699-DE304EB0-04AE-4A2E-BD6C-AB693436C08D

Q27852699-FA1E4910-EDD8-4C14-A351-DAA61896A5A0

P2860

Q27852699-00CEA290-84B1-46FD-A640-D0CFF995DC9B

Q27852699-0967D8D5-D37A-489B-BD0B-32B9D755EF1E

Q27852699-0BAC64CD-AA6A-4F29-8E39-F41D70E3998F

Q27852699-0FCA7BC9-918A-4914-8840-852C723D2035

Q27852699-11E71394-424D-48F0-A50A-68143E731B82

Q27852699-1CA2E640-F06C-4FF7-BFEB-A161F0E0DBE2

Q27852699-1E66060A-D863-4099-8DA3-DE6505A45F67

Q27852699-25BE5119-D5DC-43DB-9EF3-263E08DC5F99

Q27852699-28F44CD8-9FF1-442F-8295-A2592BA871CD

Q27852699-349AC37D-CEDA-46C3-B651-105E5E7080D6

P304

Q27852699-A9B70E96-1AC8-4BFE-8DE6-2DE9818F9F87

P31

Q27852699-035011D3-3C98-493C-9715-9BD9B79718F4

P3181

Q27852699-F9884A1F-78E4-4C58-A5CC-1E7FDAC597FC

P356

Q27852699-B2291B25-2F26-4322-B8FC-4520F81837CC

P433

Q27852699-38EB72CE-5171-4CA5-9811-523DCC8D93EC

P478

Q27852699-6BCBECC3-09B1-4CA5-A1B1-33034CB22B08

P50

Q27852699-28F753DC-E2CB-42D5-B898-391CDE96120D

Q27852699-3DAB1FE4-BBAD-40CE-93B3-B9FF7761FC03

Q27852699-623DAE94-0BD9-40F8-8186-6767B216BB88

P577

Q27852699-F91DAD01-1079-4917-AAE2-9E7A4C955631

P698

Q27852699-5AF6422F-91C0-4E59-B52F-E1A403CFD222

P921

Q27852699-BF471324-0F12-4964-BF75-28BBF4023B4B

P932

Q27852699-0D43D3B2-9DD7-429B-9DA6-958CE1978714

P3181

P356

1541-7786.MCR-13-0479-T

P1433

Molecular Cancer Research

P1476

ROS1 and ALK fusions in colore ...... ogeneity for molecular drivers

@en

P2093

Andrew J Weickhardt

http://www.w3.org/2001/XMLSchema#string

Anh T Le

http://www.w3.org/2001/XMLSchema#string

Dara L Aisner

http://www.w3.org/2001/XMLSchema#string

Diego D Paskulin

http://www.w3.org/2001/XMLSchema#string

Fiona Chionh

http://www.w3.org/2001/XMLSchema#string

Jerry Haney

http://www.w3.org/2001/XMLSchema#string

Marileila Varella-Garcia

http://www.w3.org/2001/XMLSchema#string

Nathan Schulte

http://www.w3.org/2001/XMLSchema#string

Niall Tebbutt

http://www.w3.org/2001/XMLSchema#string

Robert C Doebele

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.

ROS1 rearrangements define a unique molecular class of lung cancers.

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

P304

111-118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2240519

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1541-7786.MCR-13-0479-T

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Jennifer E Hardingham

Teresa T Nguyen

John M Mariadason

P577

2013-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24296758

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

4140177

http://www.w3.org/2001/XMLSchema#string